GSK plc American Depositary Shares (Each representing two Ordinary Shares)
GSK evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GSK—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GSK
GSK is a global biopharmaceutical company with a diversified portfolio spanning specialty medicines, vaccines, and a broad R&D pipeline, including 62 clinical-stage assets as of mid-2026.
Key risk: High debt burden
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 4 clinical trials · 1 catalyst for GSK plc American Depositary Shares (Each representing two Ordinary Shares).
GSK is a global biopharmaceutical company with a diversified portfolio spanning specialty medicines, vaccines, and a broad R&D pipeline, including 62 clinical-stage assets as of mid-2026.
- Total revenue of $32,667.0M and net income of $6,289.0M for the year ended 2025-12-31 [sec].
- Cash and equivalents of $761.0M as of 2025-12-31, with total debt of $23,771.0M [sec].
- 62 assets in clinical development as of 2026-07-28, with 20+ Phase III trial starts expected in 2026 [sec].
- Bepirovirsen (chronic hepatitis B) regulatory filings accepted in US, EU, China and Japan as of 2026-04-29 [sec].
- Ojjaara (momelotinib) granted Orphan Drug Designations in US and EU for VEXAS syndrome as of 2026-07-28 [sec].
What works
- Strong Specialty Medicines and Vaccines performance: Q2 2026 sales £8.4B (+5% CER) and core operating profit +7% CER [sec].
- Broad pipeline with 62 clinical assets and 7 asset accelerations identified across Oncology, Respiratory, Hepatology & Vaccines [sec].
- Multiple recent approvals: 5 major FDA approvals in 2025 including Nucala for COPD and Exdensur for asthma [sec].
- Bepirovirsen demonstrated statistically significant functional cure rate for chronic hepatitis B in pivotal Phase III data [sec].
What to weigh
- Total operating profit declined 75% CER in Q2 2026 (to £481M) and 31% CER year-to-date, reflecting increased R&D investment and launch costs [sec].
- High debt level of $23,771.0M versus cash of $761.0M as of 2025-12-31 [sec].
- Decision not to progress camlipixant in refractory chronic cough following CALM-1/2 Phase III results [sec].
- Currency headwinds: adverse impact on AER versus CER due to strengthening of Sterling against USD [sec].
From the filings
Quoted directly from source documents.
GSK expects 20+ Phase III trial starts in 2026
“Now expect 20+ phase III trial starts in 2026 (previously 10)”
SEC filings · July 28, 2026
Bepirovirsen regulatory filings accepted in multiple regions
“Bepirovirsen, potential functional cure for chronic hepatitis B, regulatory filings accepted in US, EU, China and Japan.”
SEC filings · April 29, 2026
GSK delivered strong 2025 performance with sales over £32 billion
“Strong 2025 performance GSK delivered another strong performance in 2025, with sales up 4% AER, 7% CER to more than £32 billion.”
SEC filings · March 6, 2026
Camlipixant development discontinued after Phase III results
“Decision not to progress further development of camlipixant in RCC following CALM-1/2 phase III results”
SEC filings · July 28, 2026
Catalyst timeline
- 2027-03-17 · Phase3_Topline — Phase 3 Topline: A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety S — Topline results from a Phase 3 study in an undisclosed indication; watch for efficacy and safety data.
Risks & what to watch (4)›
Key risks
- High debt burden — Total debt of $23,771.0M vs cash $761.0M as of 2025-12-31 [sec].
- Pipeline execution risk — Camlipixant discontinued after Phase III failure; other late-stage assets may face similar outcomes [sec].
- Currency headwinds — Strengthening Sterling vs USD negatively impacts reported AER results [sec].
- R&D cost escalation — Total operating profit declined 75% CER in Q2 2026 due to increased R&D investment [sec].
What to watch
- Bepirovirsen regulatory decisions in US, EU, China and Japan [sec].
- Phase III data readouts for efimosfermin (MASH) and Jemperli (rectal cancer) [sec].
- Launch trajectory of new approvals: Nucala (COPD), Exdensur (asthma), Blenrep (multiple myeloma) [sec].
- Progress of 20+ Phase III trial starts expected in 2026 [sec].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run GSK plc American Depositary Shares (Each representing two Ordinary Shares) through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available GSK plc American Depositary Shares (Each representing two Ordinary Shares) facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 2.83
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~199d
No insider transactions in the last 180 days
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1,031
Total value held
$17.31B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 67,661,646 | $3.73B |
| dodge & cox | 58,662,974 | $3.24B |
| primecap management co/ca/ | 25,204,538 | $1.39B |
| wellington management group llp | 11,717,613 | $646.7M |
| morgan stanley | 11,030,651 | $608.8M |
| goldman sachs group inc | 10,289,114 | $567.9M |
| royal bank of canada | 7,506,786 | $414.3M |
| state street corp | 5,998,486 | $334.0M |
| holocene advisors, lp | 5,518,433 | $304.6M |
| mondrian investment partners ltd | 4,987,393 | $275.3M |
Showing top 10 of 1,031 institutional holders of GSK plc American Depositary Shares (Each representing two Ordinary Shares). Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 0.8%
- Days to cover
- 3.4
- Shares short
- 16,061,751
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GSK short interestGovernance
Frequently asked questions
What is the AI investment thesis for GSK plc American Depositary Shares (Each representing two Ordinary Shares)?
GSK is a global biopharmaceutical company with a diversified portfolio spanning specialty medicines, vaccines, and a broad R&D pipeline, including 62 clinical-stage assets as of mid-2026.
What is GSK plc American Depositary Shares (Each representing two Ordinary Shares)'s next catalyst?
GSK plc American Depositary Shares (Each representing two Ordinary Shares)'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety S" — expected March 17, 2027.
Who is the CEO of GSK plc American Depositary Shares (Each representing two Ordinary Shares)?
Mr. Luke Victor Miels is the chief executive officer of GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK).
Where is GSK plc American Depositary Shares (Each representing two Ordinary Shares) headquartered?
GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) is headquartered in London, United Kingdom.
What therapeutic areas does GSK plc American Depositary Shares (Each representing two Ordinary Shares) focus on?
GSK plc American Depositary Shares (Each representing two Ordinary Shares) develops therapies across Oncology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.